Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1HER2-positive Breast Cancer 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Breast Cancer With Brain Metastasis 1Brain Neoplasms 1

Interventions

Cisplatin 7Paclitaxel 5Radiotherapy 4Platinum 3zimberelimab 2pembrolizumab 2nimotuzumab 2lenvatinib 2camrelizumab 2Taxes 2Injections 2Human Papillomavirus Recombinant Vaccine nonavalent 2Drug Therapy 2Carboplatin 2Brachytherapy 2trilaciclib 1toripalimab 1tislelizumab 1sintilimab 1neratinib 1fludarabine 1envafolimab 1Watchful Waiting 1Ultrasonography, Doppler 1Transurethral Resection of Prostate 1Therapeutics 1Telemedicine 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Uterine Cervical Neoplasms × neratinib × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡